PetLife Pharmaceuticals, Inc. 4
4 · PetLife Pharmaceuticals, Inc. · Filed Mar 27, 2017
Insider Transaction Report
Form 4
Salvagno Ralph T
DirectorChief Executive Officer
Transactions
- Purchase
Common Stock
2016-02-12$0.46/sh+540,000$248,400→ 890,000 total(indirect: By LLC) - Award
Employee Stock Option (right to buy)
2016-06-09+2,000,000→ 2,000,000 totalExercise: $0.25From: 2016-06-09Exp: 2019-06-09→ Common Stock (2,000,000 underlying) - Purchase
Common Stock
2016-02-12$0.64/sh+250,000$160,000→ 350,000 total(indirect: By LLC) - Purchase
Common Stock
2015-12-29$0.25/sh+100,000$25,000→ 100,000 total(indirect: By LLC) - Purchase
Common Stock
2016-02-12$0.64/sh+250,000$160,000→ 1,140,000 total(indirect: By LLC) - Award
Common Stock
2017-02-23$0.50/sh+11,160,000$5,580,000→ 12,300,000 total(indirect: By LLC)
Footnotes (3)
- [F1]Adjusted for the issuer's 1-for-5 reverse stock split effected in September 2016.
- [F2]For services valued at $0.50/share.
- [F3]The issuer granted Dr. Salvagno options to purchase 2,000,000 shares of common stock at an exercise price of 50% of the market price or $0.25/share, whichever is higher.